PMID: 7541064Jul 1, 1995Paper

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

The Journal of Infectious Diseases
R W ShaferT C Merigan

Abstract

Plasma human immunodeficiency virus (HIV) type 1 RNA levels, CD4 lymphocyte changes, and drug resistance were studied in HIV-infected patients with 200-500 CD4 lymphocytes/microL who received zidovudine and didanosine combination therapy for 2 years. Among 35 patients, 10 had sustained and 16 had transient > 10-fold reductions in HIV RNA: 9 did not have 10-fold HIV RNA reductions. Only patients with sustained HIV suppression maintained increased CD4 cell counts for 2 years (370 to 501 cells/microL; P = .006). Patients with transient HIV suppression were more likely to develop drug-resistant HIV strains (12/16 vs. 5/19, P = .01) and reverse transcriptase (RT) mutations (4.5 vs. 2.5/strain; P = .02) than were patients with sustained or no HIV suppression. Zidovudine resistance occurred with RT mutations at codons 41, 67, 70, 215, and 219. Multidrug resistance occurred with mutations at codons 62, 75, 77, 116, and 151. Mutations occurred at codons 60, 68, 118, 210, and 228 in > or = 4 patients each. Heterogeneity exists among individual virologic responses to zidovudine and didanosine combination therapy. HIV resistance mechanisms during combination therapy appear more complex than reported with monotherapy.

Citations

Nov 30, 2000·Current Infectious Disease Reports·G J Hanna, R T D'Aquila
Jun 9, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·J G García-Lerma, W Heneine
Jan 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mauro ZaccarelliAndrea Antinori
Nov 6, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·P OrlandiP Rossi
Apr 5, 2002·Clinical Microbiology Reviews·Robert W Shafer
Feb 18, 2006·PLoS Pathogens·Paul L BoyerStephen H Hughes
Apr 1, 2011·Future Microbiology·Shiro Ibe, Wataru Sugiura
May 17, 2005·Virology·Patrick ReidJ Gerardo García-Lerma
May 16, 2007·PLoS Computational Biology·Soo-Yon RheeRobert W Shafer
Feb 22, 2008·Virus Research·Javier Martinez-Picado, Miguel Angel Martínez
Aug 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark A Wainberg, Dan Turner
Oct 3, 1998·Clinical Pharmacology and Therapeutics·C V FletcherH H Balfour
Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P R Harrigan, H C Côté
Jun 17, 2020·Expert Review of Clinical Pharmacology·Andrea GiacomelliStefano Rusconi
Jul 1, 1997·Reviews in Medical Virology·E DomingoJ J Holland
Nov 25, 2003·HIV Clinical Trials·Oscar GallegoVincent Soriano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.